fasudil has been researched along with Hemangioma, Cavernous, Central Nervous System in 3 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Hemangioma, Cavernous, Central Nervous System: A vascular anomaly composed of a collection of large, thin walled tortuous VEINS that can occur in any part of the central nervous system but lack intervening nervous tissue. Familial occurrence is common and has been associated with a number of genes mapped to 7q, 7p and 3q. Clinical features include SEIZURES; HEADACHE; STROKE; and progressive neurological deficit.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Familial cerebral cavernous malformations (CCMs) in humans result from mutations of CCM2 (malcavernin, OSM, MGC4607), PDCD10 (CCM3), or KRIT1 (CCM1), a Rap1 effector which stabilizes endothelial cell-cell junctions." | 1.36 | Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. ( Awad, IA; Ginsberg, MH; Shenkar, R; Stockton, RA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Detter, MR | 1 |
| Shenkar, R | 3 |
| Benavides, CR | 1 |
| Neilson, CA | 1 |
| Moore, T | 2 |
| Lightle, R | 2 |
| Hobson, N | 1 |
| Shen, L | 1 |
| Cao, Y | 2 |
| Girard, R | 2 |
| Zhang, D | 1 |
| Griffin, E | 1 |
| Gallione, CJ | 1 |
| Awad, IA | 3 |
| Marchuk, DA | 2 |
| Shi, C | 1 |
| Austin, C | 1 |
| Zhang, L | 1 |
| Wu, M | 1 |
| Zeineddine, HA | 1 |
| McDonald, DA | 1 |
| Rorrer, A | 1 |
| Gallione, C | 1 |
| Pytel, P | 1 |
| Liao, JK | 1 |
| Stockton, RA | 1 |
| Ginsberg, MH | 1 |
3 other studies available for fasudil and Hemangioma, Cavernous, Central Nervous System
| Article | Year |
|---|---|
Novel Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Animals; Apoptosis Regulatory Proteins | 2020 |
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Neoplasms; Disease Models, Animal; Fem | 2017 |
Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animal Structures; Animals; Brain Edema; Capillary Pe | 2010 |